|
title
|
type of...
|
start
|
status
|
|
| |
|
SAKK 67/20 Open-label single-stage phase 1B...
|
clinical studies
|
2021
|
ongoing - rec...
|
|
|
An Open-Label, Multicenter, Phase 1b/2 Stud...
|
clinical studies
|
2021
|
ongoing - rec...
|
|
|
MK-7902-005 A Multicenter, Open-label Phase...
|
clinical studies
|
2021
|
scheduled
|
|
|
A multicenter, non-randomized, open-label p...
|
clinical studies
|
2021
|
scheduled
|
|
|
A Study to Evaluate Imetelstat (GRN163L) in...
|
clinical studies
|
2021
|
scheduled
|
|
|
A phase 3, multicenter, open-label, randomi...
|
clinical studies
|
2021
|
scheduled
|
|
|
A phase 3, multicenter, open-label, randomi...
|
clinical studies
|
2021
|
scheduled
|
|
|
Atezolizumab in combination with Bevacizuma...
|
clinical studies
|
2021
|
ongoing - rec...
|
|
|
SAKK 17/18 Origin
|
clinical studies
|
2021
|
scheduled
|
|
|
A PHASE II, OPEN-LABEL, MULTICENTER STUDY
|
clinical studies
|
2021
|
scheduled
|
|
|
Predictive markers for checkpoint-based imm...
|
fundamental r...
|
2020
|
ongoing - rec...
|
|
|
Lymphopenie bei myeloproliferativen Neoplas...
|
clinical studies
|
2020
|
ongoing - rec...
|
|
|
BMS CA209-914 (Checkmate 914)A Phase 3 Rand...
|
clinical studies
|
2020
|
ongoing - rec...
|
|
|
Trial: SAKK 66/17 Intratumoral injection of...
|
clinical studies
|
2020
|
ongoing - rec...
|
|
|
A phase II, open label, randomized, paralle...
|
clinical studies
|
2020
|
ongoing - rec...
|
|
|
A PHASE II, MULTICENTRE, OPEN-LABEL STUDY O...
|
clinical studies
|
2020
|
scheduled
|
|
|
A Randomized, Double-blind, Adaptive, Phase...
|
clinical studies
|
2020
|
ongoing - rec...
|
|
|
Protocol SAKK 11/16: Personalized and cell-...
|
clinical studies
|
2020
|
scheduled
|
|
| |
